ATB-346Non-steroidal anti-inflammatory drug CAS# 1226895-20-0 |
- Saquinavir mesylate
Catalog No.:BCC1922
CAS No.:149845-06-7
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Tipranavir
Catalog No.:BCC2002
CAS No.:174484-41-4
- Lopinavir
Catalog No.:BCC3621
CAS No.:192725-17-0
- Atazanavir
Catalog No.:BCC3622
CAS No.:198904-31-3
- Narlaprevir
Catalog No.:BCC1785
CAS No.:865466-24-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1226895-20-0 | SDF | Download SDF |
| PubChem ID | 25065981 | Appearance | Powder |
| Formula | C21H19NO3S | M.Wt | 365.45 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 51.6 mg/mL (141.20 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (4-carbamothioylphenyl) 2-(6-methoxynaphthalen-2-yl)propanoate | ||
| SMILES | CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OC3=CC=C(C=C3)C(=S)N | ||
| Standard InChIKey | YCNMAPLPQYQJFC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity.
IC50 value:
Target: COX-2
ATB-346 suppressed gastric prostaglandin E(2) synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine, Unlike naproxen and celecoxib, ATB-346 accelerated healing of pre-existing gastric ulcers. In a mouse airpouch model, ATB-346 suppressed cyclooxygenase-2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB-346 was as effective as naproxen in adjuvant-induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB-346 did not elevate blood pressure in hypertensive rats [1]. Treatement with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI [2]. References: | |||||
ATB-346 Dilution Calculator
ATB-346 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7364 mL | 13.6818 mL | 27.3635 mL | 54.727 mL | 68.4088 mL |
| 5 mM | 0.5473 mL | 2.7364 mL | 5.4727 mL | 10.9454 mL | 13.6818 mL |
| 10 mM | 0.2736 mL | 1.3682 mL | 2.7364 mL | 5.4727 mL | 6.8409 mL |
| 50 mM | 0.0547 mL | 0.2736 mL | 0.5473 mL | 1.0945 mL | 1.3682 mL |
| 100 mM | 0.0274 mL | 0.1368 mL | 0.2736 mL | 0.5473 mL | 0.6841 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ATB-346 is a hydrogen sulphide-releasing anti-inflammatory drug [1].
ATB-346 is a non-steroidal anti-inflammatory drug (NSAID) and shows a markedly reduced toxicity than its parent compound naproxen. In the airpouch model, ATB-346 significantly inhibited the PGE2 level and completely suppressed the whole blood TXB2 synthesis without causing gastric damage. In rats with adjuvant-Induced arthritis, administration of ATB-346 reduced the paw volume on days 14 and 21 notably. ATB-346 did not exert any damage or bleeding in the stomach or small intestine while naproxen caused bleeding in the small intestine. Besides that, administration of naproxen twice daily for 5 days in rats resulted in extensive damage in the small intestine. In contrast, same dose of ATB-346 caused quite little damage over the treatment of the 5 days [1].
References:
[1] Wallace J L, Caliendo G, Santagada V, et al. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). British journal of pharmacology, 2010, 159(6): 1236-1246.
- FLLL32
Catalog No.:BCC6499
CAS No.:1226895-15-3
- Norpterosin B
Catalog No.:BCN7101
CAS No.:1226892-20-1
- Norpterosin B glucoside
Catalog No.:BCN7302
CAS No.:1226785-88-1
- MK3102
Catalog No.:BCC6417
CAS No.:1226781-44-7
- Ibutilide Fumarate
Catalog No.:BCC5076
CAS No.:122647-32-9
- Ajugamarin H1
Catalog No.:BCN3658
CAS No.:122616-88-0
- PKC fragment (530-558)
Catalog No.:BCC5830
CAS No.:122613-29-0
- Thiazovivin
Catalog No.:BCC2525
CAS No.:1226056-71-8
- p-Anisil
Catalog No.:BCC9112
CAS No.:1226-42-2
- Garbanzol
Catalog No.:BCN6811
CAS No.:1226-22-8
- 11-Hydroxyhumantenine
Catalog No.:BCN4863
CAS No.:122590-04-9
- 11-Hydroxyrankinidine
Catalog No.:BCN4814
CAS No.:122590-03-8
- SB 277011A dihydrochloride
Catalog No.:BCC7887
CAS No.:1226917-67-4
- BAY 87-2243
Catalog No.:BCC4131
CAS No.:1227158-85-1
- 4-Fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1-(2-(trifluoromethyl)pyridin-4-yl)-1H-isoindol-3-amine
Catalog No.:BCC5113
CAS No.:1227163-56-5
- AZD3839
Catalog No.:BCC6471
CAS No.:1227163-84-9
- Liangshanin A
Catalog No.:BCN6115
CAS No.:122717-54-8
- Philanthotoxin 74
Catalog No.:BCC7478
CAS No.:1227301-51-0
- Bi-linderone
Catalog No.:BCN6116
CAS No.:1227375-09-8
- Deltorphin I
Catalog No.:BCC6233
CAS No.:122752-15-2
- [D-Ala2]-Deltorphin II
Catalog No.:BCC5723
CAS No.:122752-16-3
- StemRegenin 1 (SR1)
Catalog No.:BCC3637
CAS No.:1227633-49-9
- A 943931 dihydrochloride
Catalog No.:BCC7772
CAS No.:1227675-50-4
- SCH 39166 hydrobromide
Catalog No.:BCC7317
CAS No.:1227675-51-5
ATB-346, a novel hydrogen sulfide-releasing anti-inflammatory drug, induces apoptosis of human melanoma cells and inhibits melanoma development in vivo.[Pubmed:27777130]
Pharmacol Res. 2016 Dec;114:67-73.
Inflammation plays a key role in tumor promotion and development. Indeed, cyclooxygenase-2 (COX-2) expression is strongly associated with different types of cancer. An emerging class of compounds with significant anti-inflammatory properties is the hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs (H2S-NSAIDs). They consist of a traditional NSAID to which an H2S-releasing moiety is covalently attached. We have recently demonstrated that H2S donors inhibit melanoma cell proliferation. In the current study, we evaluated the potential beneficial effects of a new H2S-releasing derivative of naproxen, ATB-346 [2-(6-methoxynapthalen-2-yl)-propionic acid 4-thiocarbamoyl phenyl ester] which inhibits COX activity but also releases H2S. We used cell culture and a mouse melanoma model to evaluate the effect of ATB-346 on: i) in vitro growth of human melanoma cells; ii) in vivo melanoma development in mice. Cell culture studies demonstrated that ATB-346 reduced the in vitro proliferation of human melanoma cells and this effect was associated to induction of apoptosis and inhibition of NF-kappaB activation. Moreover, ATB-346 had novel Akt signaling inhibitory properties. Daily oral dosing of ATB-346 (43mumol/kg) significantly reduced melanoma development in vivo. This study shows that ATB-346, a novel H2S-NSAID, inhibits human melanoma cell proliferation by inhibiting pro-survival pathways associated with NF-kappaB and Akt activation. Furthermore, oral treatment with ATB-346 inhibits melanoma growth in mice. In conclusion, the combination of inhibition of cyclooxygenase and delivery of H2S by ATB-346 may offer a promising alternative to existing therapies for melanoma.
The hydrogen sulfide releasing compounds ATB-346 and diallyl trisulfide attenuate streptozotocin-induced cognitive impairment, neuroinflammation, and oxidative stress in rats: involvement of asymmetric dimethylarginine.[Pubmed:27088818]
Can J Physiol Pharmacol. 2016 Jul;94(7):699-708.
Hydrogen sulfide (H2S) has attracted interest as a gaseous mediator involved in diverse processes in the nervous system, particularly with respect to learning and memory. However, its therapeutic potential in Alzheimer disease (AD) is not fully explored. Therefore, the effects of H2S-releasing compounds against AD-like behavioural and biochemical abnormalities were investigated. Memory deficit was induced by intracerberoventicular injection of streptozotocin (STZ, 3 mg.kg(-1)). Animals were randomly assigned into 5 groups (12 rats each): normal control, STZ treated, and 3 drug-treated groups receiving naproxen, H2S-releasing naproxen (ATB-346), and diallyl trisulfide in 20, 32, 40 mg.kg(-1).day(-1), respectively. Memory function was assessed by passive avoidance and T-maze tasks. After 21 days, hippocampal IL-6, malondialdehyde, reduced glutathione (GSH), asymmetric dimethylarginine (ADMA), and acetylcholinestrase activity were determined. ATB-346 and diallyl trisulfide ameliorated behavioural performance and reduced malondialdehyde, ADMA, and acetylcholinestrase activity while increasing GSH. This study demonstrates the beneficial effects of H2S release in STZ-induced memory impairment by modulation of neuroinflammation, oxidative stress, and cholinergic function. It also delineates the implication of ADMA to the cognitive impairment induced by STZ. These findings draw the attention to H2S-releasing compounds as new candidates for treating neurodegenerative disorders that have prominent oxidative and inflammatory components such as AD.
The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis.[Pubmed:25755876]
Med Gas Res. 2015 Feb 27;5:4.
BACKGROUND: In experimental periodontitis, non-steroidal antiinflammatory drugs (NSAIDs) effectively inhibit the resultant alveolar bone loss. However, their deleterious gastric effects, observed in both animals and humans, dramatically limit their long-term use. It has been proven that the addition of a hydrogen sulfide (H2S)-releasing moiety to classical NSAID structures results in antiinflammatory compounds with improved gastric safeness. In this way, we decided to compare the effects of naproxen with its H2S-releasing derivative ATB-346 on ligature-induced periodontitis in rats. METHODS: Male Holtzman rats had a cotton ligature placed subgingivally around the lower right first molar during 7 days. During this period, groups of animals were daily treated with Na2S (a spontaneous H2S donor) or equimolar oral doses of naproxen (10 mg/kg) or ATB-346 (16 mg/kg). The mandibles were finally collected for histological analysis, radiographical measurements of alveolar bone loss and micro-computed tomography (muCT) analysis. Interleukin (IL)-1beta, IL-6 and IL-10 were quantified in gingiva samples, and the stomachs were also collected for scoring of tissue damage and measurement of myeloperoxidase (MPO, a marker of granulocyte infiltration). RESULTS: Ligature-induced bone loss was significantly inhibited by all the treatments, although only ATB-346 treatment resulted in significant inhibition of bone defect and other histological characteristics (such as flatness of the gingival epithelium, chronic inflammatory cell infiltration and loss of connective tissue in the gingival papillae). Both naproxen and ATB-346 inhibited the increase of gingival IL-1beta and IL-6 secondary to periodontitis, but IL-10 was unaffected. Significant damage and increased MPO contents were only found in the stomachs of the naproxen-treated animals. CONCLUSION: The H2S-releasing moiety in the ATB-346 compound not only does not impair the effects of the parent naproxen on periodontitis, but also improves bone quality and prevents the gastric mucosa damage due to prostaglandin inhibition, thus configuring a potentially new adjuvant therapy for periodontal diseases.
Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice.[Pubmed:25472548]
J Neuroinflammation. 2014 Dec 4;11:196.
BACKGROUND: Traumatic brain injury (TBI) induces secondary injury mechanisms, including dynamic interplay between ischemic, inflammatory and cytotoxic processes. We recently reported that administration of ATB-346 (2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester), a hydrogen sulfide-releasing cyclooxygenase inhibitor, showed marked beneficial effects in an animal model of spinal cord injury, significantly enhancing recovery of motor function and reducing the secondary inflammation and tissue injury. METHODS: Here we evaluated the neuroprotective potential of ATB-346, a hydrogen sulfide-releasing derivative of naproxen, using the controlled cortical impact (CCI) injury model in mice, one of the most common models of TBI. Moreover, the aim of the present study was to carefully investigate molecular pathways and subtypes of glial cells involved in the protective effect of ATB-346 on inflammatory reaction associated with an experimental model of TBI. In these studies, TBI was induced in mice by CCI and mice were orally administered ATB-346, naproxen (both at 30 mumol/kg) or vehicle (dimethylsulfoxide:1% carboxymethylcellulose [5:95] suspension) one and six hours after brain trauma and once daily for 10 days. RESULTS: Results revealed that ATB-346 attenuated TBI-induced brain edema, suppressed TBI-induced neural cell death and improved neurological function. ATB-346 also significantly reduced the severity of inflammation and restored neurotrophic factors that characterized the secondary events of TBI. CONCLUSIONS: These data demonstrate that ATB-346 can be efficacious in a TBI animal model by reducing the secondary inflammation and tissue injury. Therefore, ATB-346 could represent an interesting approach for the management of secondary damage following CNS diseases, counteracting behavioral changes and inflammatory process.
